Floatz logo

Daunorubicin

Adult Acute Lymphocytic Leukemia

Institute of Hematology & Blood Diseases Hospital, ChinaPhase 4 / ApprovedActive
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
64/ 100
Competitive Position
89/ 100

Competitive context

73 Active assets in the Adult Acute Lymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
MERCAPTOPURINE ANHYDROUS
Shanxi Bethune Hospital
Phase 4A
Cyclophosphamide
The First Affiliated Hospital of Zhengzhou University
Phase 4BBB
DEXAMETHASONE
Shanxi Bethune Hospital
Phase 4BBB
Cytosin-Arabinosid
PETHEMA Foundation
Phase 4BBB
METHOTREXATE
PETHEMA Foundation
Phase 4BBB

View all 50 →

Same molecule, other indications

Daunorubicin is also rated in:

acute myeloid leukemia by FAB classificationDormant
BBB
Indicative ·
78 / 100
View asset →
acute monocytic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →